CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.00 +2.42%

+$0.10 today

Market cap
$251.02M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.21M

Average 0.10M

Income Statement

Follow revenue through to earnings.

Revenue

$3.50M

FY 2025 · Annual

+436.5% YoY

Operating Income

-$52.06M

FY 2025 · Annual

Net Income

-$80.40M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Nov 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.84M0350K652K3.5M
Cost of Revenue173.95M0001.64M
Gross Profit121.89M(947K)350K652K1.86M
Gross Margin41.2%—100.0%100.0%53.1%
Research & Development28.44M34.77M40.62M38.82M38.2M
Selling, General & Admin100.9M10.23M11.61M14.92M17.36M
Operating Expenses134.76M45M52.23M53.74M53.92M
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
EBITDA7.49M(44.12M)(50.2M)(51.39M)(50.42M)
EBITDA Margin2.5%—-14343.1%-7882.2%-1441.5%
Operating Income(15.31M)(45M)(51.88M)(53.09M)(52.06M)
Operating Margin-5.2%—-14822.6%-8142.3%-1488.3%
Interest Income002.81M1.33M2.17M
Interest Expense15.32M6.26M000
Other Income / Expenses(14.75M)809K2.59M1.3M(28.34M)
Income Before Tax(30.06M)(44.19M)(49.29M)(51.79M)(80.4M)
Pre-Tax Margin-10.2%—-14083.1%-7943.4%-2298.5%
Income Tax Expense1.09M0000
Net Income(31.15M)(44.19M)(49.29M)(51.79M)(80.4M)
Net Margin-10.5%—-14083.1%-7943.4%-2298.5%
EPS (Basic)(0.88)(0.90)(4.07)(2.66)(2.65)
EPS (Diluted)(0.88)(0.90)(4.07)(2.66)(2.65)
Weighted Avg Shares35.25M36.1M12.12M19.51M30.38M
Weighted Avg Shares (Diluted)35.25M36.13M12.12M19.51M30.38M

CAMP Earnings Waterfall · TTM

NASDAQ:CAMP · Revenue to Net Income

Key Ratios

EPS$-2.27
Gross Margin76.9%
Net Margin-3933.1%
P/E Ratio-1.8
P/S Ratio301.8

Analysis

$3.9M of revenue converted into -$86.3M of net income for the selected period. Gross margin is 76.9% and net margin is -3933.1%, showing how much revenue survives after costs and taxes. EPS is $-2.27, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 12, 2026
10-QQuarterly reportNov 5, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
8-KCurrent reportNov 5, 2026

How much revenue does CAMP generate?

CAMP4 Therapeutics Corporation (CAMP) reported $3.50M of revenue in fiscal 2025.

Is CAMP profitable?

CAMP4 Therapeutics Corporation (CAMP) reported -$80.40M of net income, with a net margin of -2298.5%.